HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom

Antiviral Therapy

Volumn 15, Issue 7, 2010, Pages 985-991

  Chilton, Daniella N ^a,b   Castro, Hannah ^a   Lattimore, Sam ^c   Harrison, Linda J ^a   Fearnhill, Esther ^a   Delpech, Valerie ^c   Rice, Brian ^c   Pillay, Deenan ^a,c,d   Dunn, David T ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b Camden Primary Care Trust   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MIGRATION; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; UNITED KINGDOM; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TYPING;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 78651110103     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1658     Document Type: Article

References (28)

1. Descamps D, Chaix ML, Andre P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005; 38:545-552.
2. Institut de Veille Sanitaire. [First results of a new method of surveillance for HIV infection and AIDS at 30 September 2003]. Bulletin Epidémiologique Hebdomadaire 2004; 24-25:102-110. French.
3. Snoeck J, Van Laethem K, Hermans P, et al. Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001. J Acquir Immune Defic Syndr 2004; 35:279-285.
4. Holguin A, de Mulder M, Yebra G, et al. Increase of non-B subtypes and recombinants among newly diagnosed HIV-1 native Spaniards and immigrants in Spain. Curr HIV Res 2008; 6:327-334.
5. Health Protection Agency. HIV in the United Kingdom: 2008 report (Updated 25 November 2008. Accessed 20 October 2009.) Available from http://www.hpa.org.uk/web/HPAwebFile/HPAweb-C/1227515298354
6. Fox J, Hill S, Kaye S, et al. Prevalence of primary genotypic resistance in a UK centre: comparison of primary HIV-1 and newly diagnosed treatment-naive individuals. AIDS 2007; 21:237-239.
7. Booth CL, Garcia-Diaz AM, Youle MS, et al. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 2007; 59:517-524. (Pubitemid 47073459)
8. UK Group on Transmitted HIV Drug Resistance. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331:1368-1371.
9. Payne BA, Nsutebu EF, Hunter ER, et al. Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort. J Antimicrob Chemother 2008; 62:464-468.
10. Bennett DE, Bertagnolio S, Sutherland D, et al. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13 Suppl 2:1-13.
11. The UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) study. HIV Med 2004; 5:115-124.
12. UK Register of HIV Seroconverters Steering Committee. The AIDS incubation period in the UK estimated from a national register of HIV seroconverters. AIDS 1998; 12:659-667.
13. Health Protection Agency, Scottish Centre for Infection and Environmental Health, National Public Health Service for Wales, Communicable Disease Surveillance Centre Northern Ireland, Unlinked Anonymous Surveys Steering Group. Renewing the focus: HIV and other sexually transmitted infections in the UK in 2002. London: Health Protection Agency 2003.
14. BHIVA Writing Committee, BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001; 2:276-313.
15. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4:e4724.
16. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for the analysis of HIV-1 and other microbial sequences. Bioinformatics 2005; 21:3797-3800.
17. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20:W13-W23.
18. Gazzard B, BHIVA writing committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med 2005; 6 Suppl 2:1-61.
19. UNAIDS. Report on the global AIDS epidemic 2008 (Updated 6 November 2008. Accessed 28 November 2008.) Available from http://www.unaids.org/en/ KnowledgeCentre/HIVData/GlobalReport/2008/2008-Global-report.asp
20. Moore DM, Mermin J. Monitoring antiretroviral failure in resource-poor settings. Lancet 2008; 371:1396-1397.
21. Loubser S, Balfe P, Sherman G, et al. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 2006; 20:995-1002.
22. Arrive E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: meta-analysis. Int J Epidemiol 2007; 36:1009-1021.
23. Metzner KJ, Rauch P, Walter H, et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 2005; 19:1819-1825.
24. Yerly S, Rakik A, Kinloch de Loes S, et al. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconverters infected with zidovudine-resistant variants. J Virol 1998; 72:3520-3523. (Pubitemid 28188646)
25. Gallego O, de Mendoza C, Corral A, et al. Low rate of HIV-1 codon revertants in antiretroviral-experienced patients. AIDS 2003; 17:919-921.
26. Yerly S, Jost S, Telenti A, et al. Infrequent transmission of HIV-1 drug-resistant variants. Antivir Ther 2004; 9:375-384.
27. Hamers RL, Wensing AM, Siwale M, et al. Prevalence of drug-resistant HIV-1 variants at initiation of standard first-line HAART in Africa. Antivir Ther 2009; 14 Suppl 1:A178.
28. Hughes GJ, Fearnhill E, Dunn D, et al. Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom. PLoS Pathog 2009; 5:e1000590.